UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 21, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	**001-36150**	**33-0344842**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

4955 Directors Place
San Diego, CA 92121
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (858) 203-4100

N/A
(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol**	**Name of each exchange on which registered**
Common Stock, $0.0001 par value	SRNE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Information.

On January 21, 2022, Sorrento Therapeutics, Inc. (the "Company") posted under the "Investors" section of the Company's website at www.sorrentotherapeutics.com a corporate presentation providing an overview of the Company's Potent Omicron Neutralizing Antibody (nAb) STI-9167 IV and STI-9199 IN (the "Presentation"). A copy of the Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1	Sorrento Therapeutics, Inc. Corporate Presentation Regarding Sorrento Potent Omicron Neutralizing Antibody (nAb) STI-9167 IV and STI-9199 IN.
104	Cover Page interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.

Date: January 21, 2022

By: /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman, President and Chief Executive Officer

Exhibit 99.1

sorrento
Therapeutics

Sorrento Potent Omicron Neutralizing Antibody (nAb)
STI-9167 IV
STI-9199 IN

Disclaimer

Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the "Company") and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate," "projected" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA's or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company's formulations and products and regulatory filings related to the same, and receipt by the Company of milestone and royalty payments may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's Form 10-K, 10-Q and 8-K reports.

In presenting this material or responding to inquiries in connection with a presentation, management may refer to results, projections or performance measures that are not prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") as reported in the Company's SEC filings. These results, projections or performance measures are non-GAAP measures and are not intended to replace or as a substitute for results measured under GAAP, but rather as supplement to the GAAP reported results.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its Securities and Exchange Commission ("SEC") filings on Forms 10-K, 10-Q and 8-K, and investors are advised to consult the Company's filings for a more complete listing of risk factors, contingencies and uncertainties effecting the Company and its business and financial performance.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

ZTlido™ and G-MAB™ are trademarks owned by Scilex Pharmaceuticals, Inc. and Sorrento, respectively.

Seprehvir®, is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.

All other trademarks are the property of their respective owners.

Discovery of STI-9167



Human anti-SARS CoV-2 antibody families

Family	Clone (#s)	VHH CoV2-spike (IC50)	VDJ (Heavy)	VJ (Kappa)
A	2	490-1000pM	VH3-53/DH6-19/JH3	VK1-9/JK2
B	16	50-440pM	VH1-8/DH3-10/JH6	VK3-20/JK3
C	1	10pM	VH3-49/DH6-13/JH4	VK3-15/JK1
D	4	70-125pM	VH4-4/DH3-19/JH4	VK3-15/JK2
E	1	115pM	VH3-53/DH3-9/JH6	VK3-15/JK4
F	6	5-130pM	VH3-23/DH2-21/JH4	VK1-39/JK1

STI-9167 Binding to S1 Domain of SARS-CoV-2 Variants of Concern (VOCs)



Variant RBD	ka (1/Ms) Ab STI-9167	kd (1/s) Ab STI-9167	KD (M) Ab STI-9167	Rmax (RU) Ab STI-9167	Chi² (RU²) Ab STI-9167
WA-1	2.27 ± 0.2 E+05	1.40 ± 0.03 E-03	6.20 ± 0.44 E-09	97.2 ± 4.3	1.19 ± 0.30
Delta	3.02 ± 0.2 E+05	1.34 ± 0.04 E-03	4.45 ± 0.22 E-09	124.3 ± 7.6	2.17 ± 0.33
Omicron	1.99 ± 0.1 E+05	4.50 ± 0.10 E-03	2.26 ± 0.08 E-08	104.6 ± 5.0	0.22 ± 0.02

Analyte: WA-1, Delta, or Omicron spike S1 domain
Instrument: Biacore T200

STI-9167 Binding Kinetics to Spike S1 Domain Compared to Those of EUA-approved nAbs

Binding Affinity Spike S1 Omicron



Analyte: Omicron spike S1 domain
Instrument: Biacore T200

STI-9167 Binding to SARS-CoV-2 VOC Spike Proteins Expressed on HEK293 Cells



cell-expressed spike binding EC50 (µg/mL)	
Variant spike	Ab STI-9167
WA-1	0.025
Delta	0.011
Omicron	0.025
Omicron + R346K	0.023

Omicron Variant and Omicron + R346K Mutation Infection Statistics



To date: No SARS-CoV-2 nAb approved or in development has been shown to have potent neutralization activity (≤ 100 ng/ml) against the Omicron + R346K variant

SARS-CoV-2 Spike-Pseudotyped VSV Neutralization Assay

Variant lineage	nAb IC_{50} (µg/ml)
	STI-9167
D614G	0.0036
Alpha (B.1.1.7)	0.0029
Beta (B.1.351)	0.0195
Gamma (P.1)	0.0063
Delta (B.1.617.2)	0.0054
Delta Plus (B.1.617.2.1)	0.0033
Epsilon (B.1.429)	0.0040
Zeta (P.2)	0.0034
Iota (B.1.526)	0.0194
Iota (B.1.526.2)	0.0024
Kappa (B.1.617.1)	0.0090
Lambda (C.37)	0.0027
Mu (B.1.621)	0.0186
Omicron (B.1.1.529)	0.0148
Omicron+R346K (B.1.1.529)	0.0239



STI-9167 Superior Neutralization Activities Against Omicron and Omicron+R346K Variants in SARS-CoV-2 Spike-Pseudotyped VSV Neutralization Assays

IC50 (ug/mL)

Variant Lineage	STI-9167	Cilgavimab (AZ)	Tixagevimab (AZ)
D614G	0.0036	0.0353	0.0056
Omicron (B.1.1.529)	0.0148	9.105	0.6386
Omicron+R346K (B.1.1.529)	0.0239	>10	0.4696







Neutralization Activity of STI-9167 in the SARS-CoV-2 Live Virus Neutralization Assays



Virus neutralization IC50 (ng/mL)

Virus	Ab STI-9167
WA-1	6.041
Delta	13.7
Omicron	54.29

Superior Neutralization Activity of STI-9167 as Compared to EUA-approved Neutralization Antibodies (nAbs) in the SARS-CoV-2 Live Omicron Virus Neutralization Assays



Omicron virus neutralization IC_{50} ng/ml

STI-9167	**34.4**
Tixagevimab	**198.9**
Cilgavimab	**326**
Sotrovimab	**573.1**
Bamlanivimab + Etesevimab	**> 2000**
Casirivimab + Imdevimab	**> 2000**



- Vero cells infected with 500 pfu Omicron variant virus
- Infection visualized with anti-SARS-CoV-2 nucleoprotein antibody

STI-9167 Neutralizing Activity Following IN or IV Administration in the K18-hACE2 Transgenic Mouse Model of COVID-19



STI-9167 GMP Manufacturing and Clinical Developmental Status

- ✓ **STI-9167 GMP Master Cell Bank generation completed**
- ✓ **STI-9167 GMP Drug Product to supply Phase 1/2 studies formulated for intranasal and intravenous dosing has been F/F**
  - ✓ **Already manufactured enough drug substance for 100,000's of intranasal doses**
- ✓ **IND-enabling preclinical safety and toxicology studies completed**
- • **IND submission in early February**
- • **Phase 1 clinical trials planned in healthy individuals and infected patients for both intranasal formulation (COVIDROPS) and intravenous formulation (COVISHIELD)**